Background. The system of IGF-I and its binding proteins is a complex system with many physiological functions
including metabolic regulations. Present study was aimed to describe changes of its particular components in patients
with type 1 and type 2 diabetic patients and patients with obesity.
Methods and Results. We examined 21 patients with obesity, 13 patients with type 2 and 22 with type 1 diabetes
in comparison with 16 age matched healthy controls. We performed clinical examination and estimation of serum
concentrations of IGF-I, free-IGF-I, IGFBP-1, -2, -3 and -6, insulin, C-peptide and fasting glucose. Patients with
obesity featured by decreased IGF-I (p<0.05), free-IGF-I (p<0.05), IGFBP-1 (p<0.01) and IGFBP-3 (p<0.05) serum
levels. Type 2 diabetes were associated with a decline of IGF-I (p<0.05) and IGFBP-2 (p<0.05) serum levels. Type
1 diabetes was characterised by typical decrease in IGF-I (p<0.05), free-IGF-I (p<0.01) and IGFBP-3 (p<0.01) serum
levels as well as by increase in IGFBP-1 (p<0.01) serum levels. Type 2 diabetic patients had lover IGFBP-2 and
higher IGFBP-1 and IGFBP-6 levels than obese subjects.
Conclusions. The study showed a changes in the system of IGF-1 and its binding proteins associated with studied
metabolic diseases that confirm active participations of this system in carbohydrate metabolism regulation.
IGF-I, IGFBP, diabetes mellitus, obesity.